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Abstract
In studies of hominin adaptations to fire use, the role of the aryl hydrocarbon receptor (AHR) in the evolution of
detoxification has been highlighted, including statements that the modern human AHR confers a significantly better
capacity to deal with toxic smoke components than the Neanderthal AHR. To evaluate this, we compared the AHR-
controlled induction of cytochrome P4501A1 (CYP1A1) mRNA in HeLa human cervix epithelial adenocarcinoma cells
transfected with an Altai-Neanderthal or a modern human reference AHR expression construct, and exposed to 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD). We compared the complete AHR mRNA sequences including the untranslated
regions (UTRs), maintaining the original codon usage. We observe no significant difference in CYP1A1 induction by TCDD
between Neanderthal and modern human AHR, whereas a 150–1,000 times difference was previously reported in a study
of the AHR coding region optimized for mammalian codon usage and expressed in rat cells. Our study exemplifies that
expression in a homologous cellular background is of major importance to determine (ancient) protein activity. The
Neanderthal and modern human dose–response curves almost coincide, except for a slightly higher extrapolated max-
imum for the Neanderthal AHR, possibly caused by a 50-UTR G-variant known from modern humans (rs7796976). Our
results are strongly at odds with a major role of the modern human AHR in the evolution of hominin detoxification of
smoke components and consistent with our previous study based on 18 relevant genes in addition to AHR, which
concluded that efficient detoxification alleles are more dominant in ancient hominins, chimpanzees, and gorillas than in
modern humans.
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Introduction
The use of fire is a defining characteristic of the human lin-
eage, with pyrotechnology being one of the most powerful
tools developed during human evolution. Fire afforded
humans with benefits affecting many domains of the human
niche, including diet, defense against predators, thermoregu-
lation, and social interaction (Carmody and Wrangham 2009;
Wrangham 2009; Wiessner 2014).
However, pyrotechnology also came with (lesser known)
costs (Henry et al. 2018), including toxicological ones (Aarts
et al. 2016). The utilization of fire fueled with wood or other
types of biomass on a daily basis implies frequent exposure to
toxic components of smoke, to which polycyclic aromatic
hydrocarbons (PAHs) contribute importantly (Freeman and
Cattell 1990). In view of the well-known reproduction-toxic
effects of tobacco smoke (DeMarini 2004; Dechanet et al.
2011) and the very similar composition of smoke from burn-
ing any type of biomass (Mishra et al. 2005; Naeher et al.
2007), the capacity to detoxify smoke toxicants is a crucial
fitness factor inferred to have been under positive genetic
selection in hominin populations ever since they started using
open fire regularly.
The chronology of fire use is unclear: Some scholars advo-
cate a long chronology, with routine fire use starting with
Homo erectus, more than 2 Ma (Wrangham 2009;
Wrangham and Carmody 2010). Based on archaeological
data, others see consistent fire use as a significantly later phe-
nomenon, from around 350,000 years ago onward (Roebroeks
and Villa 2011; Shimelmitz et al. 2014), whereas regular fire
production has even been inferred to be a modern human
accomplishment only (Sandgathe et al. 2011); but see
Sorensen (2017) and Sorensen et al. (2018). In an attempt
to shed independent light on the debated chronology, Aarts
et al. (2016) hypothesized that frequent exposure to toxic
compounds occurring in smoke would have resulted in ge-
netic adaptations in genes involved in detoxification of these
toxicants. They analyzed 36 genetic variants in a comprehen-
sive set of 19 relevant genes in Neanderthal, Denisovan, and
(pre)historic and extant anatomically modern human
genomes. This study showed that archaic hominins predom-
inantly possessed protective gene variants, as do extant chim-
panzees and gorillas. In contrast, the number of less
protective, “high-risk” alleles has increased in modern
humans. This pattern starts with the earliest modern human
genome, of the Ust’-Ishim individual from 45,000 years ago
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(Fu et al. 2014), and is suggestive of a deterioration in the
ability to deal with smoke toxicants in modern humans, start-
ing long before the emergence of agriculture. The more effi-
cient detoxification of smoke toxins by Neanderthals and
Denisovans was apparently hitchhiking on old primate mech-
anisms likely involved in dealing with plant toxins, and pos-
sibly in balancing certain photooxidation products induced
by exposure to UV light (Wincent et al. 2012).
Cytochrome P450 1A1 (CYP1A1) plays an important, du-
alistic role in the defense against PAH intoxication, being
involved both in phase 1 detoxification of PAHs and, along
with this reaction, in the generation of mutagenic radical-type
intermediates (Nebert et al. 2013; Divi et al. 2014). The
CYP1A1 gene is under transcriptional control of the aryl hy-
drocarbon or Ah receptor (AHR) (Corchero et al. 2001;
Nukaya and Bradfield 2009), a ligand-activated key regulator
of many detoxification genes (Köhle and Bock 2007). In ad-
dition to dioxins and dioxin-like compounds such as 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), and PAHs such as ben-
zo[a]pyrene (BaP), the AHR is activated by a very diverse
range of agonist molecules (Denison et al. 2011). Therefore,
the AHR gene variant and the resulting detoxification pheno-
type of ancient hominins are an important aspect of the
evolution of smoke detoxification.
Starting from an evolutionary hypothesis comparable to
Aarts et al. (2016), Hubbard et al. (2016) focused on the AHR
gene, for which humans display a fixed difference (Val381)
from the Neanderthal and Denisovan (Ala381) ancestral var-
iant. Hubbard et al. (2016) performed an analysis of the mod-
ern human versus the Neanderthal AHR in rat cells and
concluded that the Neanderthal AHR induced CYP1A1
mRNA expression with an effective concentration 50%
(EC50) between 150- and 1,000-fold lower than observed
with the human AHR, implying a profound evolutionary
change.
Here we report a complementary study following their
approach and focusing on the AHR, but with important
differences in experimental setup based on the literature on
AHR biology and function (Okey et al. 1989; Ema, Ohe, et al.
1994; Poland et al. 1994; Pohjanvirta et al. 1998; Moriguchi
et al. 2003), in particular the reported impaired signaling by
the human AHR in a nonhuman cellular background attrib-
uted to cofactor incompatibility issues (Moriguchi et al. 2003).
Furthermore, it is well documented that the 50- and 30-
untranslated regions (UTRs) of a gene transcript may be in-
volved in expression regulation of its gene product, mainly by
affecting the translation rate and/or the stability of the tran-
script (Hinnebusch et al. 2016; Mayr 2017). Consequently,
variations in the UTR sequence were found to be involved
in the etiology of human diseases, including relatively rare
neurologic disorders such as X-linked Charcot–Marie–
Tooth disease, but also more common morbidities such as
Alzheimer’s dementia, and breast and other types of cancer
(Chatterjee and Pal 2009), corroborating their potential
importance.
These previously reported observations and mechanistic
considerations prompted us to apply a modified setup. Most
importantly, we chose to test the complete Neanderthal AHR
mRNA sequence in a human instead of a rat cellular back-
ground. Therefore we included the 30- and 50-UTR in the AHR
sequences compared, comprising four instead of two single-
nucleotide variants (SNVs) while leaving the original codon
usage intact. These modifications led to a very different result:
No physiologically relevant difference in CYP1A1 transcription
activation was observed between the ancient and modern
AHR variants, which disagrees with a major role for the AHR
in the evolution of smoke detoxification. This finding is con-
sistent with our previous risk profiling study of hominin de-
toxification gene variants (Aarts et al. 2016).
Results
The Ancient and Modern AHR mRNA Sequences
Studied Differ at Four Positions
To determine the degree of sequence identity between the
ancient hominin and modern human AHR mRNAs, we com-
pared the ancient AHR genomic sequences with the human
reference genome (assembly GRCh38/hg38). The splicing do-
nor and acceptor sites and ten adjacent bases upstream and
downstream of the 20 exon–intron borders in the modern
AHR reference transcript (Ensembl ID: ENST00000242057.8)
were represented with 100% fidelity in the Altai- and Vindija-
Neanderthal and Denisovan AHR gene, and were even very
conserved from deeper down the primate lineage, justifying
to assume no differences in the exon structure of the ancient
and modern AHR transcripts studied here. Comparison of the
ancient AHR mRNA sequences thus deduced from the pub-
lished genomic sequences (supplementary material S10,
Supplementary Material online) with the human reference
genome revealed differences at six positions (fig. 1). The SNVs
observed in the three ancient hominin sequences (Altai- and
Vindija-Neanderthal and Denisovan) were almost identical
except for position 73 in the 50-UTR, where the Vindija-
Neanderthal was heterozygous, but the C-allele was still
matching the ancient hominin consensus and therefore cho-
sen to be tested; and furthermore, at position 5439 of the 30-
UTR the Neanderthals seem to have acquired a lineage-
specific A deletion variant, since it is found in both the
Altai- and Vindija-Neanderthal genomes (in the heterozygous
state), whereas it seems absent in the Denisovan. Hence, the
5438–5439 CA allele was found most representative for the
available ancient genomes and therefore studied here.
Altogether, as the ancient variants at positions 73 and
5438–5439 chosen were identical to the modern human ref-
erence, four sites remained different between the ancient and
modern AHR mRNA sequences studied. Supplementary ma-
terial S1, Supplementary Material online, shows an alignment
of all sequences studied here and by Hubbard et al. (2016).
The HeLa Cell Strain Used Is Suitable for AHR Variant
Testing
The human cervix epithelial adenocarcinoma cell line HeLa
has been reported as a cell system with very low endogenous
AHR expression validated for testing AHR gene variants
(Koyano et al. 2005). Other studies, including this one (sup-
plementary material S4, Supplementary Material online),
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generally report lower (Vorrink et al. 2014) to much lower
(Singh et al. 1996) AHR mRNA or protein expression than in
liver-derived cell lines. To further corroborate the suitability of
the HeLa cell strain used in this study we transfected these
cells with the empty pcDNA3.1/Zeo(þ) vector used to con-
struct expression vectors for the AHR variants to be com-
pared, and measured the level of AHR mRNA overexpression
achieved in this cell strain upon transfection with the con-
structed Neanderthal and modern human AHR expression
vectors (details in Materials and Methods). We hold the view
that the level of exogenous AHR overexpression is, in fact, the
key factor in this experimental setup, not the background
response as such. We observed a more than 1 order of mag-
nitude (17–141 times) increase in the AHR mRNA level upon
transfection with the AHR expression constructs as com-
pared with empty vector (see supplementary material S4,
Supplementary Material online). The excess of exogenous
AHR will obviously outcompete the endogenously expressed
receptor and largely prevent it from taking part in signal
transduction. Expression of the Ah receptor repressor
(AHRR) was reported to be relatively high in HeLa cells
(Tsuchiya et al. 2003) and reduce CYP1A1 inducibility, but
AHRR will be similarly outcompeted, because it is binding to
the same dioxin-responsive element (DRE) as the AHR, result-
ing in an inducibility of 2–4 times (supplementary material S4,
Supplementary Material online) as reported before (Nakajima
et al. 2003). Moreover, we applied mathematical modeling of
the contribution by the exogenous and endogenous AHR to
the overall CYP1A1 induction response to demonstrate that
this level of overexpression is amply sufficient to reveal a
range of EC50 differences from as low as 10 times up to
1,000 times (supplementary material S4, Supplementary
Material online). Our goal was to compare the transactivation
capacity of the modern human and Neanderthal AHR var-
iants including any possible effect of these variants on AHR
mRNA or protein expression. One of the SNVs studied here
(A/G at position 185 of the 50-UTR) is known as an extant
polymorphism (rs7796976) reported to affect AHR mRNA
levels (Prager et al. 2016). The relevant experimental factor
to carefully control is therefore the copy number of AHR
expression constructs introduced into cells. We have applied
two independent controls to ensure that this would not differ
significantly between the HeLa cells transfected with the
modern human and the Neanderthal AHR expression con-
structs: 1) cotransfection with an enhanced green fluorescent
protein (EGFP) expression vector, enabling to visualize the
transfection efficiency by fluorescence microscopy (fig. 2a–
f); and 2) quantitative polymerase chain reaction (qPCR) of
the mRNA expressed from the zeocin resistance gene expres-
sion cassette (ZEO) present on the backbone of the AHR
expression constructs, which is a quantifiable measure pro-
portional to the copy number of functional AHR expression
constructs inside cells (fig. 2g). This approach avoids measur-
ing expression vector molecules that were carried over during
cell harvesting, or were damaged.
FIG. 1. Map of the modern human and ancient hominin AHR mRNA sequence variants studied here and by Hubbard et al. (2016). The modern
human AHR variant tested was based on manually expert-curated sequence information from the Ensembl and RefSeq databases (details in
Materials and Methods). The bar gives a scaled representation of this 6,277-bp sequence including the 50-UTR, the AHR protein-coding region, and
the 30-UTR. The numbers above are the coordinates of the variant sites within the Ensembl AHR reference transcript ENST00000242057.8. Below it,
the base, or codon plus encoded amino acid (V, valine; A, alanine; R, arginine; K, lysine) present in each AHR variant is indicated. Cross-hatching
indicates optimization for mammalian codon use and minimal secondary mRNA structure; absence of hatching indicates that the codon usage
from the human reference sequence is maintained. Codon bases in bold italics differ naturally, respectively, in the synthetic sequences tested by
Hubbard et al. (2016), have been changed as compared with the modern human reference. Apart from the indicated variable sites the reported
ancient AHR transcript sequences are identical to the modern reference sequence (see supplementary materials S1 and S10, Supplementary
Material online).
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We took note of preliminary observations that HeLa cells
also showed CYP1A1 induction upon transfection with the
AHR expression constructs without cotransfection with an
Ah receptor nuclear translocator (ARNT) expression con-
struct. We therefore measured the endogenous ARNT
mRNA level in HeLa and in HepG2 cells (see supplementary
material S4, supplementary fig. S4.1, Supplementary Material
online). This showed that the AHR-deficient HeLa cells
expressed about two times higher endogenous ARNT
mRNA levels than the notoriously AHR-competent human
hepatocellular carcinoma cell line HepG2 (Zeiger et al. 2001),
hence confirming that ARNT levels were not limiting AHR-
mediated responses in these HeLa cells. Therefore, we omitted
the cotransfection with ARNT in our main experiments in
contrast to the original protocol (Koyano et al. 2005).
The CYP1A1 Induction Response Is Similar in Human
Cells Transfected with Neanderthal and Modern
Human AHR
HeLa cells were transfected with an expression construct for
either the Altai Neanderthal or the modern human AHR (for
details, see above and Materials and Methods). The
transfected HeLa cell population was exposed to a 0–10,000
pM TCDD concentration range, and the dose–response curve
for induction of CYP1A1 mRNA expression was determined
(fig. 3). The curves for the cells transfected with the modern
human and the Neanderthal AHR almost coincide. Upon
fitting the one-site receptor-ligand binding equation to the
data (see Materials and Methods, section Data Processing and
Statistics), only a small difference in the extrapolated maximal
CYP1A1 induction was observed (Neanderthal AHR attains
an 8.3% higher maximum), not in the basal level and the EC50
(table 1). This shows that cells transfected with either the
Altai Neanderthal or the modern human AHR reference
cDNA sequence essentially respond similarly to exposure to
TCDD.
The G185A SNV in the 50-UTR of the AHR mRNA
Affects Reporter Gene Expression
At position 185 of the 50-UTR (fig. 1) the modern human AHR
mRNA carries a newly derived A variant (rs7796976 of dbSNP
build 153, TopMed data set: A allele frequency¼ 0.21) which
is unique for the human lineage among all presently se-
quenced primate genomes. The Neanderthal and the
Denisovan carry the ancestral G variant (fig. 1), but the
FIG. 2. HeLa cells were transfected with a pcDNA3.1/Zeo(þ)-based expression construct for the complete modern human (panels a, c, e) or
Neanderthal AHR mRNA (panels b, d, f). Panel a–f) Cotransfection (1:1 w/w) with the EGFP expression plasmid pcDNA3-EGFP to visualize the
transfection efficiency; a, b) EGFP fluorescence; c, d) EGFP fluorescenceþ phase-contrast transillumination; e, f) transillumination only; the black
marker spot is applied for orientation. The pcDNA3.1/Zeo(þ) vector backbone is carrying a zeocin resistance gene expression cassette (ZEO).
Therefore, ZEO mRNA expression is proportional to the number of functional construct molecules inside the cells upon transfection and allows to
quantify the transfection efficiency by qRT-PCR. To correct for possible differences in cDNA input, the ZEO mRNA levels as quantified by qRT-PCR
were normalized for b-actin (ACTB) mRNA expression and the mean and standard error of the mean (SEM) of the ZEO/ACTB mRNA ratio (n¼ 13)
was plotted (panel g). A t-test on the difference in mean ratio between the transfections with the modern human and Neanderthal AHR expression
constructs showed no significant difference (P< 0.648).
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anatomically modern human from Ust’-Ishim (45,000 years
ago) (Fu et al. 2014) is already heterozygous (see supplemen-
tary material S6, Supplementary Material online). Smoking
and possessing the G-variant were found to additively in-
crease intestinal permeability in Crohn’s inflammatory bowel
disease (Prager et al. 2016), demonstrating the functional rel-
evance of this 50-UTR polymorphism. Moreover, the high-risk
185G variant was found associated with enhanced AHR
mRNA expression in colon biopsies.
We wondered whether we could confirm the functional
effect of this 50-UTR variant in the context of the Neanderthal
and modern human reference AHR mRNA sequences studied
here. Therefore, we tested the effect of the G185A variation
on EGFP reporter gene expression as a proxy for its possible
effect on the AHR mRNA and/or protein expression. Either
the 185G or 185A 50-UTR sequence was attached to the 50-
end of the EGFP coding region within an EGFP fusion protein
expression vector. These constructs were transfected into the
FIG. 3. Dose–response relation observed for CYP1A1 mRNA induction by TCDD in HeLa human cervix epithelial adenocarcinoma cells transfected
with a modern human or Neanderthal AHR expression construct. Each curve is based on two data sets from different HeLa cell batches, and each
data set comprised mostly three, or at least two TCDD exposure replicates per data point. Cytochrome P450 1A1 (CYP1A1) and b-actin (ACTB)
mRNA expression were measured in duplicate by qRT-PCR, and CYP1A1 mRNA expression was normalized to b-actin mRNA expression. The
CYP1A1/ACTB ratios were subsequently normalized to the basal level for the modern human AHR, that is, this value was set to 1 and all values
expressed as a fold value relative to this response level, and plotted against the TCDD concentration in the culture medium during exposure. Error
bars indicate the standard error of the mean (SEM). Dose–response curves were generated by fitting the one-site receptor-ligand binding equation
to the experimental data (see Materials and Methods, section Data Processing and Statistics), which produced best-fit estimates for the Effective
Concentration 50% (EC50), and for the basal and maximal values of TCDD-induced CYP1A1 mRNA expression (table 1). For comparison full-range
dose–response curves as reported by Hubbard et al. (2016) are shown in gray based on their observed EC50 values and a toxic equivalency factor
(TEF) for TCDF¼ 0.1 to account for the AHR agonist potency difference between TCDF used by them and TCDD (TEF¼ 1) used in this study (Van
den Berg et al. 2006). *The maximal CYP1A1 induction levels attained by the modern human and Neanderthal AHR were statistically evaluated as
different based on the calculated difference in corrected Akaike’s information criterion (column DAICc in Table 1).
Table 1. Comparison of the Parameters of the Dose–Response Relation for CYP1A1 mRNA Induction by TCDD in HeLa Cells Transfected with an















Probability (%) That Parameter Is
From To From To Same Different
Bottom 1.000 0.8428 1.156 1.126 0.9629 1.287 21.009 62.35 37.65 Same
Top 5.103 4.756 5.453 5.526 5.184 5.871 0.805 40.07 59.93 Different
EC50(pM) 4,097 2,837 5,834 3,450 2,443 4,806 21.811 71.21 28.79 Same
NOTE.—95% CI, 95% confidence interval for the curve-fitting parameter as reported by GraphPad Prism 8; DAICc, difference in corrected Akaike’s Information Criterion (AIC)
between the simpler model where the parameter is the same for both data sets and the more complex model where the parameter is different for each data set.
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human liver cell line HepG2, which is known to express all
factors required for fully functional AHR signal transduction
(Zeiger et al. 2001), and hence will be able to reflect the
natural function of the AHR 50-UTR. It was observed that
the fluorescence signal was approximately 1.3 times higher
when the 185G 50-UTR variant, occurring in the ancient
hominins, was inserted before the EGFP reporter (fig. 4).
This is consistent with the functional effects of these 50-
UTR variants observed by Prager et al. (2016).
Discussion
As ancient hominin cells cannot be reconstructed to date, the
“next best” and feasible option to obtain relevant functional
information regarding ancient gene variants is expression in a
modern human cellular background. The HeLa human cervi-
cal adenoma cell line is particularly suitable to carry out the
comparison between the ancient and modern AHR, as it has
been reported as valid for functional testing of AHR gene
variants (Koyano et al. 2005), because of a low background
of endogenous AHR, and nevertheless expressing all essential
components, such as ARNT (this study), to support AHR
signaling upon transfection with an AHR expression con-
struct. Besides ensuring a homologous cellular background,
our study compares the complete ancient hominin AHR tran-
script with the modern human reference, including the 50-
and 30-UTR with two SNVs in addition to the two SNVs
occurring in the coding region, while leaving the original co-
don usage intact.
Applying these test conditions, we observed that the
Neanderthal AHR has a very similar transactivating potency
as compared with the modern human AHR: no significant
difference in basal level and EC50 for induction of CYP1A1
mRNA by TCDD, and only a small difference in the maximal
induction level (8.3% higher), found at very high TCDD con-
centrations, above 3 nM of TCDD toxic equivalents (TEQ). It
is debatable, however, whether such high on-target concen-
trations are still relevant for real-life exposure levels.
Significant variation among modern humans has been ob-
served regarding the dissociation constant (Kd) for the bind-
ing of TCDD to the AHR, respectively, the EC50 for
downstream AHR-controlled effects, such as CYP1A1 induc-
tion (Roberts et al. 1990; Harper et al. 2002; Silkworth et al.
2005; Van den Berg et al. 2006; Forgacs et al. 2013). The cited
references report a 0.087–18 nM range. The EC50 for CYP1A1
mRNA induction observed by us (4.1 nM) and by Hubbard
et al. (2016) (0.5 nM 2,3,7,8-tetrachlorodibenzofuran [TCDF],
equivalent to 0.05 nM TCDD) appear to lay in the upper and
just below the lower part of this range, respectively.
These results also apply to the Denisovan because its AHR
mRNA sequence is identical to the tested Altai-Neanderthal
sequence (fig. 1), and are likely to be representative for the
Vindija-Neanderthal as well. Its AHR mRNA has a deviation
from the Altai sequence at two UTR positions at the most,
dependent on the allele considered and the unknown hap-
lotype coupling of these differences, which have not been
reported in modern humans to be of any physiological rele-
vance (dbSNP, build 153).
The Effect of the Ancient 185G 50-UTR Variant on
Gene Expression Is Similar as Reported in Modern
Humans
The ancestral 185G AHR 50-UTR variant found in the ancient
hominins studied (fig. 1, supplementary fig. S6,
Supplementary Material online) is still abundant in the
present-day human population at a 79% frequency (dbSNP
build 153, rs7796976), and was found associated with an ep-
ithelial barrier defect in smokers with Crohn’s disease and
higher AHR mRNA expression (Prager et al. 2016). The in-
creased EGFP reporter protein expression observed to be
conferred by the 185G 50-UTR variant as compared with
the 185A variant (fig. 4) is consistent with these findings,
and provides evidence for the functional significance of the
185G 50-UTR variant observed in the ancient AHR sequences.
FIG. 4. Effect of the G185A polymorphism (rs7796976) observed in the
50-UTR of the AHR transcript on EGFP expression. A 620-bp 50-UTR
sequence carrying either the 185G or 185A variant was attached to
the 50-side of the EGFP coding region within pcDNA3-EGFP, a cyto-
megalovirus promoter-driven EGFP fusion protein expression vector,
and transfected into AHR-competent HepG2 human liver hepatoma
cells. EGFP reporter protein expression directed by the EGFP mRNA
carrying the AHR-derived 50-UTR was normalized to the luciferase
expression directed by a cotransfected constitutive luciferase expres-
sion construct (see Materials and Methods). Data are from four rep-
licate transfections carried out with two different HepG2 cell batches.
To compensate for differences in responsivity between cell batches,
all data are presented relative to the mean response observed for the
185A variant. This box and whisker graph is presenting the difference
in distribution of the data, with the box showing the 25–75% percen-
tile range, calculated including the median (horizontal line), and
mean (x), and the whiskers indicating the minimum and maximum
value.
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Its effect on protein expression is likely due to an effect on
translation efficiency or a posttranscriptional effect on AHR
mRNA levels.
Other Genes Playing a Role in Deactivation of
Environmental Toxins
The new results presented here imply that the Ala381Val
mutation that became fixed in the modern human lineage
might be less relevant for the evolution of Ah receptor-
controlled detoxification than suggested by Hubbard et al.
(2016). Instead, many more genes have been shown to be
involved in detoxification of dioxin-like toxicants (Moorthy
et al. 2015), which appeared to be predominantly in the an-
cestral, protective state in ancient hominins, whereas less
protective variants appear in the modern human lineage
(Aarts et al. 2016).
Limited Impact of the Ala381Val Substitution in the
Modern Human Lineage
In a human cellular background, no significant difference in
EC50 for CYP1A1 induction was found between the modern
Val381 and ancient hominin Ala381 AHR protein variants,
suggesting no or only a small difference in AHR sensitivity to
the prototypical agonist TCDD. At first sight, this may seem at
odds with previous comparative studies reporting a higher
affinity for TCDD of “Ala-type” (mouse Ala375/rat Ala379) as
compared with “Val-type” (human Val381/mouse Val375)
AHRs. This amino acid difference mostly results in EC50 values
around ten times lower for AHR-mediated effects of the Ala-
type receptors (Ema, Matsushita, et al. 1994; Okey et al. 2005;
Silkworth et al. 2005; Connor and Aylward 2006; Flaveny et al.
2009; Budinsky et al. 2010). The Neanderthal receptor, the
first “humanized” Ala-type receptor ever studied, with a
reported 150- to 1,000-fold difference in EC50 for CYP1A1
induction when compared with the modern human Val-
type AHR in rat cells (Hubbard et al. 2016) seems to be an
extreme case of this tendency. How to explain this discrep-
ancy? A review of the previously published experimental and
molecular modeling literature on the difference between the
two types of AHR revealed extensive argumentation support-
ing our observations. Below these arguments have been cat-
egorized according to 1) the role of the variation in AHR
protein size, 2) effects of species-specific and reciprocal allo-
steric interactions within the AHR complex, 3) methodolog-
ical limitations, and 4) evidence from molecular modeling.
First of all, the best-fit EC50 estimate observed here in a
human cellular background for the Neanderthal Ala-type
AHR was still slightly lower than the best-fit value found
with the modern human Val-type AHR, and may, in fact,
be up to approximately two times lower based on the calcu-
lated 95% confidence intervals (table 1). Therefore, although
we observed a smaller than ten times EC50 difference between
the ancient hominin Ala381 and modern human Val381 AHR
types, this result is still qualitatively consistent with the pre-
viously reported difference. But even a close similarity in EC50
may, on second thought, not be so surprising in view of the
following theoretical considerations and reported
observations:
Role of AHR Protein Length
The initial comparative studies on the human AHR, and the
AHR from dioxin-sensitive and -resistant mouse and rat
strains showed that the observed length variation of the
AHR polypeptide (albeit in opposite directions for mouse
and rat, and only for limited toxic endpoints [Okey et al.
2005] for the rat) has an equally important impact on its
functionality as the Ala>Val mutation (Ala379Val never in-
vestigated in rat) (Ema, Ohe, et al. 1994; Pohjanvirta et al.
1998).
Effects of Species-Specific and Reciprocal Allosteric
Interactions within the AHR Complex
The Ala>Val variation has been extensively studied in cellular
backgrounds compatible with the Ala-type AHR, for instance,
rodent (Okey et al. 1989; Poland and Glover 1990; Hubbard
et al. 2016) and monkey (Ema, Ohe, et al. 1994; Silkworth et al.
2005; Connor and Aylward 2006; Hubbard et al. 2016), but to
the best of our knowledge, never the other way around. In
particular lacking are studies of an Ala-type receptor in Val-
type AHR-compatible (i.e., human) cells, since before the dis-
covery that ancient hominins still carried the ancestral Ala381
variant in a human-like polypeptide context there was no
logical incentive to do so. Our study therefore seems to be
the first of this type.
The affinity for a ligand is obviously an intrinsic property of
a receptor, primarily determined by the stereochemical inter-
action characteristics of a receptor-ligand pair. However, ev-
idence is accumulating, for the androgen receptor (Baek et al.
2006; Claessens et al. 2017; Senapati et al. 2020) and other
nuclear receptors (NRs) (Billas and Moras 2013; De Vera et al.
2017), supporting the view that in vivoin vivo functioning of
NRs and other ligand-activated transcription factors such as
the AHR involves extensive communication between func-
tional domains. This applies both to functional domains
within a receptor and to domains in other components of
the receptor complex, such as the dimerization partner, chap-
erones, and cofactors. These interdomain interactions may be
modulated by the interaction with various ligands and vari-
able DNA response element configurations and nucleotide
sequences. Therefore, the ultimate transactivation outcome
will depend on the integral result of all interactions and allo-
steric effects that may occur between ligands, protein
domains, and response element nucleotides within the ulti-
mate DNA-bound receptor complex taking part in assembly
of the transcription machinery in the upstream gene regula-
tory region, and of such interactions during the steps leading
up to it. Most importantly, the above-mentioned interactions
and allosteric effects are considered to act in a reciprocal way.
Seok et al. (2017) determined the crystal structure of a mouse
AHR–human ARNT heterodimer in complex with a DRE and
concluded for the specific case of the AHR: “. . . the complex
dimerization and interdomain interfaces remotely control
target DNA binding and the induction of AHR activity, which,
. . ., suggests an allosteric structural pathway for mediating
changes from the ligand-binding PAS-B domain to the DNA-
reading head, or reciprocally, from the DNA-reading head to
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the ligand-binding domain or farther to the transactivation
domain” (Seok et al. 2017, p. 5434).
Zhang et al. (2008) found that the potency of prototypical
AHR agonists, including TCDD used here and TCDF used by
Hubbard et al. (2016), to induce transactivation in a two-
hybrid AHR-coactivator interaction assay was dependent
on the species and tissue origin of the cell type in which
the AHR–coactivator interaction was studied. Although this
study did not take into account the possible effect of ARNT
on the AhR–coactivator interaction, it clearly showed the
potential of cell-specific factors such as coactivators to mod-
ulate AHR agonist potency.
Furthermore, domain swapping experiments between the
guinea pig and mouse AHR by Henry and Gasiewicz (2008)
showed that the C-terminal part of the receptor, containing
the transactivation domain, and not the ligand binding do-
main (LBD) itself, determines whether 30-methoxy-40-nitro-
flavone will act as an AHR agonist or not (and even turn into
an antagonist) (Henry and Gasiewicz 2008). This concept is
also supported by a range of experimental observations show-
ing that binding of an activated (nuclear) receptor to its re-
sponse element via the DNA binding domain induces
allosteric effects in other domains which may affect the di-
merization interface, coregulator recruitment or even ligand
potency. De Vera et al. (2017), for example, reported for the
case of the PPARc–RXRa heterodimer: “DNA binding prop-
agates a conformational change in PPARc–RXRa, stabilizes
the receptor LBD dimer interface, and impacts ligand potency
and cooperativity in NR coactivator recruitment” (De Vera
et al. 2017, p. 1506). Similarly, for the androgen receptor there
are reports of this phenomenon (Zhou et al. 1995; Langley
et al. 1998; He et al. 2000; Helsen et al. 2012; Meijer et al. 2019),
as there are for other NRs (Shao et al. 1998; Gee et al. 1999;
Helsen and Claessens 2014; De Vera et al. 2017; Meijer et al.
2019).
Furthermore, the mouse AHR protein was shown to com-
prise, in addition to several synergistic stimulatory subdo-
mains, an inhibitory subdomain in its C-terminal trans-
activating domain which interacts with heat-shock protein
HSP90 and functions in a species-, cell type-, and promoter-
specific way (Whitelaw et al. 1994; Ma et al. 1995).
This reciprocal allosteric cross-talk concept opens up an
avenue along which changes in interfaces with species- (or
cell-)specific dimerization partners, chaperones, coactivators
or other cofactors interacting with the AHR during signal
transduction may have an effect on the conformation of
the ligand or DNA binding domain, and thereby affect the
ligand or DNA binding affinity of the AHR complex as it
occurs in vivoin vivo, and consequently, influence the EC50
values of AHR agonists observed for AHR-controlled
responses in a species- (or cell-) specific way.
Methodological Limitations
As a matter of fact, due to technical limitations AHR ligand
and DNA binding studies have necessarily been incompre-
hensive regarding the above-mentioned relevant interactions,
for example, using in vitroin vitro translated AHR variant and/
or ARNT protein preparations lacking other relevant cell fac-
tors (Pandini et al. 2007), or ARNT (Chiaro et al. 2008;
Hubbard et al. 2015), cytosol (Ema, Ohe, et al. 1994; Flaveny
et al. 2009) or response element DNA (Bank et al. 1992; Singh
et al. 1996; Hubbard et al. 2015) of heterologous origin. In view
of the existence of extensive (allosteric) interactions, these
limitations may have contributed to the apparent divergence
of previous TCDD affinity and DNA binding measurements
from the results reported here.
Pandini et al. (2007) reported an anomaly observed with
the Ala375Val mutation in the mouse AHR. Although they
did not observe any TCDD binding by Val375 AHR, this var-
iant appeared to still have 42% of the DNA binding capacity
of the Ala375 variant; it required changing Ala375 to the
much bulkier leucine (Leu) to completely prevent DNA bind-
ing, suggesting that the effect of Val375 may not, or only
partially result from steric hindrance (see their table 4). The
authors hypothesize a number of technical causes which are
plausible indeed, but quantitatively leave a gap. Therefore we
propose a possible additional biological explanation, which
would be consistent with our observations: The [3H]TCDD
binding assay reaction was carried out with in vitroin vitro
translated AHR only, whereas the DNA binding assay was
carried out in the presence of ARNT. A possible interpretation
of their observation would be that the Val375 AHR complex
was in a different conformation in the presence of ARNT,
causing a proportional difference between the ligand-
induced DNA binding by the ultimate DNA-bound complex
at chemical equilibrium and, on the other hand, the level of
ligand binding at equilibrium to the AHR in isolation. These
experimental data are therefore consistent with our view that
the “penetrance” of the Ala>Val variation is dependent on
the ultimate composition, and hence the conformation, of
the ligand-activated AHR/ARNT/cofactor/DNA complex
formed, which is obviously species-dependent.
Evidence from Molecular Modeling
Bonati et al. (2017) recognized that, for that matter, analo-
gous limitations apply to molecular modeling and ligand
docking studies with the AHR: “To reach a better predictive
ability, in silicoin silico modeling should move toward a mo-
lecular description of the entire process by which ligands
differentially affect the AhR activation, stimulate AhR trans-
formation and DNA binding, and activate AhR-dependent
gene expression” (Bonati et al. 2017, p. 45).
In addition to the possibility that cell-specific allosteric
effects play a role, a range of molecular modeling outcomes
and experimental observations are arguing against the per-
ception that the in vivoin vivo effect of the Ala>Val substi-
tution is mainly the consequence of its effect on ligand
binding:
A recent molecular docking simulation using a 3D homol-
ogy model of the basic–helix–loop–helix (bHLH) - Per–Arnt–
Sim (PAS) ligand binding and dimerization domain from the
murine AHR (mAHR), which followed a new approach taking
into account receptor flexibility, revealed that the per-residue
contribution of Ala375 in the mAHR to the free energy
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decrease (DGbind) of TCDD binding is minimal (Giani
Tagliabue et al. 2019), essentially implying no role for
Ala375 in stabilizing TCDD in the ligand binding pocket of
the mAHR. This implies that Ala375 binding does not explain
the higher affinity for TCDD of the mouse Ala-type AHR, or,
by analogy, the very much higher affinity and potency in rat
cells in case of the Neanderthal AHR (Hubbard et al. 2016) as
compared with the Val-type AHRs, although this does not
exclude that steric hindrance would play a certain role. The
somewhat, but not much more bulky Val residue (with an
isopropyl instead of a methyl side chain) may indeed block
TCDD to a certain extent from entering the ligand binding
pocket. Against steric hindrance by the Val side chain argues,
however, that Ema, Ohe, et al. (1994) observed no effect on
TCDD binding of changing Val381 in the human AHR to Leu
(with an even more bulky side chain) or to Gly (no side-chain
at all). In contrast, it required changing the nonpolar Val381
into the dissimilar polar amino acid aspartic acid (Asp) to
effectively abolish TCDD binding, which would be consistent
with the nature of the interaction with another amino acid
side chain being the crucial issue (Ema, Ohe, et al. 1994).
Similarly, A361 and A375 of the mouse AHR are on adja-
cent strands of the b-sheet that is modeled to form one side
of the ligand cavity (Procopio et al. 2002). Changing Ala361 to
the larger but still nonpolar amino acids Val or Leu
completely eliminated TCDD binding and TCDD-induced
DRE binding. However, changing the adjacent Ala362 into
Leu had much less effect, especially on DNA binding, which
was still 69% of the wild-type level (Henry and Gasiewicz 2008,
calculated based on their figure 2a). This, again, may indicate
that another mechanism than steric hindrance may play a
role in causing the effects of these mutations at position 361,
362, and (by analogy) 375 of the mouse AHR LBD.
Furthermore, the mere fact that the amino acid at position
381 is located near the end of the human AHR amino acid
chain making up the LBD (amino acids 247–391) (Bisson et al.
2009) makes it more likely, regardless of the way of polypep-
tide chain folding, to engage in interactions outside the LBD,
and thus to have an indirect, allosteric effect on agonist
potency.
Altogether these experimental, 3D modeling and molecu-
lar docking data, and methodological limitations provide sub-
stantial evidence that the discrepancy between the
experimental results described here and previous studies, if
perceived as contradictory in the first place, can be explained
by 1) allosteric effects due to heterologous AHR dimerization
partners, chaperones, coactivators or other protein factors
interacting with the AHR (complex), for example, when
expressed in cells from a heterologous species; and 2) the
use of in vitroin vitro test conditions lacking some in vivoin
vivo AHR complex constituents. Finally, in view of the obvious
difference in sensitivity to TCDD between the ancient hom-
inin AHR with Ala381 (observed in this study to be compa-
rable to the modern human Val-type AHR) and the rodent
Ala-type AHRs (reported in many in vitroin vitro and in vivoin
vivo studies to be approximately ten times more responsive
to TCDD than the human Val-type AHR; see above), it cannot
be excluded, that the many existing species differences in
amino acid sequence other than the one at position 381
(see supplementary material S9, Supplementary Material on-
line) are playing a role. Most importantly, our results imply a
caveat against the use of cellular models derived from heter-
ologous species in gene product expression and characteriza-
tion studies.
Several Evolutionary Mechanisms May Explain Val381
Fixation
As our results imply no difference between the AHR from
Neanderthals and modern humans with regard to activation
by the standard AHR agonist TCDD, the question arises why
the Val381 variant has reached fixation in the modern human
lineage. It is possible that there is still a significant physiolog-
ical difference between these AHR variants toward other
agonists than dioxin-like compounds, or AHR antagonists,
such as bioactive plant food components (Denison et al.
2011), or endogenous AHR ligands such as tryptophan pho-
tooxidation products that need to be balanced at optimal
levels (Wincent et al. 2012). Theoretically, we cannot
completely exclude that this also pertains to TCDF used by
Hubbard et al. (2016). If so, this may contribute to the dis-
crepancy with our study, but actually, this is very unlikely,
because TCDD and TCDF are both generally recognized as
very similar full AHR agonists (Kopec et al. 2010) that have, to
the best of our knowledge, never been reported to display
divergent toxicity before. Besides that, it would not argue in
any way the physiological relevance of the diverging results
reported here for the prototype AHR agonist TCDD.
Altogether, the Val381 AHR variant may still confer a fit-
ness advantage related to such alternative AHR-active com-
pounds which could have driven the fixation process. Two
other possible mechanisms that do not involve positive ge-
netic selection of the AHR Val381 variant itself are conceiv-
able: 1) fixation by random genetic drift, which could have
been enhanced by the small size of early modern human
populations (Whitlock 2000; Meyer et al. 2012; Prüfer et al.
2017); and 2) positive selection on a gene that is genetically
tightly linked to the AHR locus. A candidate could be the
genomic region reported to be ranking at position 21 in terms
of selective sweep strength in the modern human lineage,
which is about 1 Mb from the AHR locus (chromosome 7:
18339385–18546684 in genome assembly GRCh38/hg38; see
table S37 in Green et al. [2010]). This region contains one
gene, HDAC9, encoding histone deacetylase 9. Histone deace-
tylation provides a tag for epigenetic repression and plays an
important role in transcriptional regulation, cell cycle progres-
sion, and developmental events (Mejat et al. 2005; Delcuve
et al. 2012). In view of the close vicinity of the HDAC9 gene it is
possible that, early in the modern human lineage, the AHR
Val381 variant was driven to fixation because of the lack of
recombination between the newly arisen AHR Var381 variant
and the selective sweep region containing HDAC9.
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No Major Role of AHR in Neandertal Detoxification
Capacity of Smoke-Related Toxic Compounds,
Consistent with Our Previous Study
As far as the deep history of fire use is concerned, our previous
study (Aarts et al. 2016) was inconclusive regarding the use of
fire by Neanderthals and Denisovans, as the high prevalence
of low risk, but mostly ancestral detoxification gene variants
in their genome did not allow conclusions regarding positive
genetic selection. Modern humans, on the other hand,
appeared to be evolving toward decreased detoxification ef-
ficacy in spite of their stronger dependence on fire use. The
results presented here do not change this assessment, and are
strongly at odds with suggestions that a mutation in the AHR
may have given modern humans an evolutionary advantage
over Neanderthals in adapting to smoke exposure.
Future Directions
With a view to future research into the physiological proper-
ties of ancient hominin gene variants it appears crucial to
reconstruct their expression conditions as faithfully as possi-
ble, especially the cell type used, which should be preferen-
tially of human origin. We showed here that there is no
essential difference between the ancient and modern AHR
regarding activation by the toxic AHR agonist TCDD also
occurring at low levels in smoke. It remains to be seen, how-
ever, whether this indifference extrapolates to all classes of
AHR-active compounds, including major smoke toxins such
as PAHs. Such studies, in particular of dietary and endogenous
AHR agonists will be crucial to understand the full biological
impact of the observed ancient AHR variations.
Materials and Methods
Detailed Ancient AHR Variant Testing Strategy
UTRs of a gene transcript may contain functional elements
embedded in the primary sequence, or hairpins or other sec-
ondary structures serving as protein or micro-RNA binding
sites that play a role in translation initiation and regulation,
mRNA stability, transport from the nucleus, or cellular local-
ization (Hinnebusch et al. 2016; Mayr 2017). Specifically for
the AHR mRNA a 50-UTR variant has been described in the
modern human (rs7796976) that increases AHR mRNA ex-
pression (Prager et al. 2016) and also occurs in the ancient
hominin AHR sequences studied here (position 185 in fig. 1).
For the AHR 30-UTR, a binding site for micro-RNA 124 was
recently described (Liu et al. 2018) involved in regulating its
expression level as well. Furthermore, changing the natural
codons may affect the protein translation efficiency and the
ultimate expression level as compared with the natural
mRNA sequence (Brule and Grayhack 2017). It may therefore
produce artifacts in the functional analysis of the AHR var-
iants and distort their comparison when applied to amino
acids at positions where they are different (Ala, Val, Arg, Lys).
Therefore, we tested the complete and original AHR mRNA
sequence, including the 50- and 30-UTR, without mammalian
codon optimization.
Synthesis of Modern Human and Neanderthal AHR
cDNA Sequences
The modern human AHR variant tested (fig. 1) was the
Ensembl AHR transcript AHR-201 (ENST00000242057.8)
which is based on expert-curated sequence information
and has been assigned the “gold” status, implying that this
transcript is identical between Ensembl automated annota-
tion and VEGA/Havana manual curation (Cunningham et al.
2019; EMBI-EBI 2020). An extra T deoxynucleotide was added
to its 30-terminus based on RefSeq AHR mRNA record
NM_001621.4, which is also manually curated (NCBI 2017).
The Altai-Neanderthal AHR mRNA sequence carrying four
single nucleotide changes as compared with the modern hu-
man reference was selected to be tested (see Results). It was
retrieved from the VCF data files published (Prüfer et al. 2014,
2017) as described in supplementary material S10,
Supplementary Material online. A synthetic double-
stranded copy DNA (cDNA) of the modern human AHR
mRNA reference sequence (supplementary material S2,
Supplementary Material online) and of the Altai-
Neanderthal derivative generated by site-directed mutagene-
sis (supplementary material S3, Supplementary Material on-
line) were purchased from BaseClear (Leiden, the
Netherlands). Both synthetic sequences were verified to be
100% correct by Sanger sequencing.
Construction and Preparation of AHR Expression
Constructs
The synthetic modern human and Altai-Neanderthal cDNA
sequences were produced including 50-terminal PstI and 30-
terminal XhoI restriction sites which were used to insert them
into the expression vector pcDNA3.1/Zeo(þ) (Invitrogen,
Fisher Scientific, Landsmeer, the Netherlands) using standard
recombinant DNA techniques (Sambrook and Russell 2001).
These expression constructs were propagated in Escherichia
coli DH5a and plasmid DNA was isolated using the E.Z.N.A.
Endo-Free Plasmid DNA Mini Kit II (Omega bio-tek, VWR,
Breda, the Netherlands) to obtain endotoxin-free plasmid
DNA suitable for transfection. For unknown reasons, specif-
ically for the Neanderthal variant plasmid, the best yield was
obtained when starting from a single, freshly grown bacterial
colony and doubling the normal ampicillin level during prop-
agation to 200mg/ml. The identity of the obtained plasmid
preparations was confirmed again by Sanger sequencing
around the Ala381Val variation site (fig. 1, C/T at position
1785) using the primers listed in supplementary material S8,
Supplementary Material online.
Human Cell Culture and Transfection
The human cervix epithelial adenocarcinoma cell line HeLa
was purchased from the American Type Culture Collection,
and the liver carcinoma cell line HepG2 from the European
Collection of Authenticated Cell Cultures (Sigma-Aldrich
Chemie N.V., Zwijndrecht, the Netherlands). General cell cul-
ture supplies were from Gibco (Life Technologies Europe B.V.,
Bleiswijk, the Netherlands) if not indicated otherwise: HeLa
cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) þ 4.5 g/l D-glucose þ L-glutamine þ 25 mm
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HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
without pyruvate (42430-025) to which MEM nonessential
amino acids (11140-035) were added and 10% fetal bovine
serum (Sigma, F7524, Sigma-Aldrich Chemie N.V). HepG2
cells were cultured in Eagle’s Minimum Essential Medium
(EMEM) þ Earle’s salts without L-glutamine (21090-022) to
which MEM nonessential amino acids (11140-035) were
added and 10% fetal bovine serum (American Type Culture
Collection, ATCC 30-2020, LGC Standards GmbH, Wesel,
Germany).
For transfections, HeLa and HepG2 cells were seeded at
approximately 80% density in 96-well plates (Greiner Bio-One
655180). HeLa cells were transfected using the TransIT-
HeLaMONSTER Transfection Kit (MIR 2904) and HepG2 cells
with TransIT-LT1 Transfection Reagent (MIR 2304) applying
the standard protocols (both from Mirus Bio LLC, Sopachem
B.V., Ochten, the Netherlands).
Exposure of Transfected HeLa Cells
Forty to forty-four hours after transfection, three replicate
wells with HeLa cells were exposed per concentration of
TCDD to be tested by adding an equal volume of medium
containing twice the final concentration. TCDD (purity 98%,
Schmidt B.V., Amsterdam, the Netherlands) was dissolved in
dimethyl sulfoxide (spectrophotometric grade, purity 99,9%,
Acros Organics 167852500, Fisher Scientific) as a vehicle to
add it to culture medium (final concentration 0.4% v/v di-
methyl sulfoxide). The concentration of the TCDD parent
solution used to prepare the dilution series was calibrated
by gas chromatography–mass spectrometry analysis. As
TCDF used by Hubbard et al. (2016), TCDD is also a full
AHR agonist with a ten times greater potency to activate
the AHR (WHO-TEF of TCDF is 0.1 [Van den Berg et al.
2006]).
AHR 50-UTR—EGFP Reporter Gene Fusion Constructs
The modern human reference and ancient AHR mRNA
sequences differ consistently at position 185 of the 50-UTR
(numbering of fig. 1; r.-459g>a using HGVS nomenclature
[den Dunnen et al. 2016] based on translation start). Both
50-UTR variants were generated by PCR using Phusion High-
Fidelity DNA polymerase (New England Biolabs M0530) and,
as a template, the full-length AHR cDNA clone SC119159
purchased from Origene (delivered in vector pCMV6-XL4;
distributor Acris Antibodies GmbH, Herford, Germany). A
segment from this construct (bp 918–1,612) carrying the
complete SC119159 50-UTR (185A-variant) and an upstream
EcoRI restriction site was amplified using primers pCMV6-
XL4_918-937 and AHR_ENST643-630_XhoI, the latter includ-
ing a 30-terminal XhoI restriction site and a 6-bp clamp (se-
quence details and annealing temperature in supplementary
material S8, Supplementary Material online). The ancient G-
variant of this segment was generated by overlap extension
PCR (Heckman and Pease 2007). The upper mutated overlap
segment (bp 918–1,169 of SC119159) was generated using
the primer pair pCMV6-XL4_918-937 and AHR_ENST200-
170_185G_rev, and the lower mutated overlap segment
(bp 1,142–1,612) with primer pair AHR_ENST173-
203_185G_fwd and AHR_ENST643-630_XhoI. Before fusion
PCR, both segments were column-purified using the GeneJET
PCR Purification Kit K0702 (Thermo Scientific, K0702, VWR,
Breda, the Netherlands). The fusion reaction of these seg-
ments contained 100 pg of the short (252 bp) and 200 pg of
the long fragment (471 bp; overlapping 28 bp with the shorter
segment), 10mM of primers pCMV6-XL4_918-937 and
AHR_ENST643-630_XhoI, 10 mM dNTPs, 1 Phusion HF
Buffer, and 1 unit of Phusion DNA polymerase in 50ml reac-
tion volume. After initial denaturation at 98 C for 30 s this
reaction mixture was subjected to five cycles of 10 s 98 C,
3 min 55 C, and 30 s 72 C, followed by a finishing incubation
at 72 C for 5 min. The undetectable amount of fusion prod-
uct formed was column-purified using the GeneJET PCR
Purification Kit and reamplified using the outer primers
pCMV6-XL4_918-937 and AHR_ENST643-630_XhoI. The
generated fusion product (707 bp) was column-purified,
digested with EcoRI and XhoI, again column-purified, and
then ligated applying standard cloning techniques into
EcoRI- and XhoI-digested and subsequently gel-purified
pcDNA3-EGFP, a cytomegalovirus immediate-early pro-
moter/enhancer-controlled EGFP fusion protein expression
vector (gift from Doug Golenbock; RRID: Addgene_13031;
available from Addgene, Cambridge, MA). The resulting con-
struct was propagated in E. coli DH5a according to standard
methods (Sambrook and Russell 2001) and purified for trans-
fection of human HepG2 cells using the E.Z.N.A. Endo-free
Plasmid DNA Mini Kit II (Omega Bio-tek D6950-01, VWR,
Breda, the Netherlands). The A- or G-variant type and insert
sequence of the final plasmid preparations was confirmed to
be 100% correct by Sanger sequencing. An aligned overview
of the vector template, primers, overlap segments, overlap
extension product, vector insert, and AHR 50-UTR aligned to
the human AHR mRNA reference sequence is available in
supplementary material S7, Supplementary Material online.
Quantification of Protein Expression Directed by the
AHR 50-UTR-EGFP Fusion mRNA
The 185A or 185G AHR 50-UTR-EGFP fusion mRNA con-
structs were cotransfected (ratio 1:1) with pBV-Luc (He
et al. 1999) (a gift from Bert Vogelstein; RRID:
Addgene_16539; available from Addgene), carrying a firefly
luciferase coding sequence under control of a minimal pro-
moter, into HepG2 cells known to feature natural AHR ex-
pression and signaling (Zeiger et al. 2001). EGFP expression
was measured using a 96-well fluorescence plate reader
(Tecan Infinite M200 PRO) using the standard settings for
EGFP quantification. EGFP expression was normalized for
transfection efficiency based on the luciferase expression con-
ferred by the cotransfected pBV-Luc plasmid, which was
quantified using flash kinetics and a double injector auto-
mated plate reader (Glomax 96 E6521, Promega
Corporation, Madison, WI) to subsequently inject luciferase
substrate (Flash Mix according to Boerboom et al. [2006]) and
0.2 M sodium hydroxide stop reagent.








be/article/38/4/1292/5991403 by guest on 01 June 2021
Measuring mRNA Expression Levels Using
Quantitative PCR
Dose–response curves for the induction of CYP1A1 mRNA
expression by TCDD exposure were determined after 24 h of
exposure using quantitative reverse transcription PCR (qRT-
PCR). AHR mRNA to assess the level of overexpression, zeocin
resistance gene (ZEO) expression to quantify transfection ef-
ficiency, as well as b-actin (ACTB) mRNA expression levels
were determined in sample aliquots measured in parallel. All
qRT-PCR data, including background AHR and ARNT mRNA
levels measured in HeLa and HepG2 cells, were normalized for
differences in cDNA input based on ACTB mRNA expression.
Harvesting of cells from 96-well cell culture plates and qRT-
PCR was carried out using the Ambion Power SYBR Green
Cells-to-CT Kit (Thermofisher Scientific 4402954).
Alternatively, for small-scale experiments and nontransfected
HeLa and HepG2 cells, total RNA was isolated using TRIzol
reagent (Invitrogen, Fisher Scientific), reverse transcribed into
cDNA using the iScript cDNA Synthesis Kit, and quantitative
PCR was carried out using IQ SYBR Green Supermix (both
from Bio-Rad Laboratories B.V., Veenendaal, the
Netherlands). All primers and annealing temperatures used
are listed in supplementary material S8, Supplementary
Material online. Melt-curve analysis was performed to assure
a single PCR product of the expected melting temperature. A
Bio-Rad CFX Connect thermocycler was used throughout.
Data Processing and Statistics
Dose–response data were analyzed using GraphPad Prism
8 software to determine the best fit to the data of the equa-
tion Y¼ Bottomþ [X * (Top-Bottom)/(EC50þ X)], describ-
ing the relation between the response (Y ¼ CYP1A1 mRNA
level) and the agonist concentration (X ¼ concentration
TCDD) for a receptor with one ligand binding site such as
the AHR. The output includes best estimates for the basal
(Bottom) and maximal CYP1A1 induction level (Top), and for
the agonist concentration inducing a half maximal response
(EC50) as well as a 95% confidence interval for these curve
fitting parameters. The output values of these parameters for
the modern human and Neanderthal AHR were statistically
evaluated as different or not based on the difference in cor-
rected Akaike’s information criterion values (DAICc) as cal-
culated by GraphPad Prism 8 (GraphPad Software 2020).
Supplementary Material
Supplementary data are available at Molecular Biology and
Evolution online.
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